I think if we’re worried about JAK inhibitor safety, we need to be doing it right. I wrote this for @RheumNow for #EULAR2024 ahead of my debate against @Janetbirdope, but also drew my inspiration from @RADoctor in @ACR_Journals - a must read: https://t.co/RA6ktQAzqO https://t.co/lltDbtxpAg

• The Art of Communicating Risk and Benefit to Promote Shared Decision‐Making, In…
• https://twitter.com/rheumnow/status/1801615707999756628

important session worth reading the full recommendations - TNF tick of approval @RheumNow #EULAR2024 https://t.co/ORDocVie11

• https://twitter.com/drpnash/status/1801664265461338298/photo/1

#EULAR2024 Please find my short blog on the Impact of Safety Warning Update on the use of JAK-inhibitors @RheumNow https://t.co/Z4pujQRQ9h https://t.co/QRUnJInblH

• Impact of regulatory warning on JAK inhibitors | RheumNow
• https://twitter.com/Yuz6Yusof/status/1801655701107790163/photo/1

RA patients on abatacept have an appalling immunogenic response to Shingrix. Humoral fades away in the first year, and an absence of cellular responses. Alarming and need strategies to combat this #EULAR2024 POS0620 Winthrop/@RADoctor @RheumNow https://t.co/8gY9ocLBDp

• https://twitter.com/drdavidliew/status/1801641070629109908/photo/1

#EULAR2024 POS0390 What impact of regulatory warning on JAK-i on access to therapy? Data from UK BSSR-BR reported 4 in 5 #RA patients would have been considered ‘high-risk’. Of these, 28% had failed ≥3 biologics; so no suitable alternatives. Enormously impacted @RheumNow https://t.co/XeS9qHXSpH

• https://twitter.com/Yuz6Yusof/status/1801634766610964984/photo/1